Glucantime 1.5g/5ml Injection Meglumine Antimoniate In Pakistan

Glucantime 1.5g/5ml Injection Meglumine Antimoniate In Pakistan

Glucantime 1.5g/5ml Injection contains meglumine antimoniate, a pentavalent antimonial medicine used in the treatment of certain forms of leishmaniasis, including visceral and cutaneous disease in appropriate clinical settings. Treatment choice depends on the type of leishmaniasis, parasite species, patient’s condition, and geographic location.

The 5ml ampoule contains approximately 405mg of pentavalent antimony (Sb5+), equivalent to about 81mg Sb5+ per ml. Because dosing is based on pentavalent antimony content rather than simply the total meglumine-antimoniate weight, treatment should be calculated by an experienced healthcare professional.

Benefits

• Used as an antileishmanial treatment in appropriate patients.
• Contains meglumine antimoniate, a pentavalent antimonial compound.
• May be used for selected forms of cutaneous or visceral leishmaniasis.
• Available as an injectable formulation for specialist-administered treatment.
• Provides a standardized source of pentavalent antimony when an antimonial regimen is clinically appropriate.

Specifications

The exact packaging and manufacturer information should be verified on the original product pack before use.

How To Use

Glucantime should only be administered according to a specialist’s prescription. The dose is calculated according to the patient’s body weight, the type of leishmaniasis, disease severity, and the amount of pentavalent antimony required.

• Do not self-inject this medicine.
• Administration may be intramuscular, intravenous, or intralesional depending on the clinical indication and prescribed treatment protocol.
• The healthcare professional should calculate the required volume from the pentavalent-antimony concentration.
• Treatment duration varies according to the form of leishmaniasis and the applicable treatment guideline.
• Cardiac, liver, and kidney function may need monitoring during systemic treatment.

Important Safety Information

Meglumine antimoniate can cause significant adverse effects, including cardiac rhythm abnormalities, QT prolongation, liver toxicity, kidney problems, pancreatitis, and blood-count abnormalities. ECG and laboratory monitoring may therefore be required during treatment.

Patients with significant heart, liver, or kidney disease require particular caution, and treatment decisions should be made by an experienced clinician.

Product authenticity is especially important: WHO previously reported falsified products labelled as Glucantime/meglumine antimoniate circulating in Pakistan and Iran. Verify the manufacturer, packaging, batch number, expiry date, and authorized supply source before administration.

Why Choose Glucantime 1.5g/5ml?

• Contains meglumine antimoniate, an established pentavalent antimonial medicine.
• Specifically used in the management of selected forms of leishmaniasis.
• Provides a defined pentavalent-antimony concentration for weight-based clinical dosing.
• Injectable formulation suitable for specialist-supervised treatment.
• Appropriate treatment can be selected according to the patient’s disease type and clinical circumstances.